ATORXS Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.80 |
| 52 Week High | SEK 0.80 |
| 52 Week Low | SEK 0.80 |
| Beta | 1.15 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -91.53% |
| 5 Year Change | -97.66% |
| Change since IPO | -97.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATORXS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.3% | 2.2% |
| 1Y | n/a | -18.3% | 8.0% |
Return vs Industry: Insufficient data to determine how ATORXS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ATORXS performed against the UK Market.
Price Volatility
| ATORXS volatility | |
|---|---|
| ATORXS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ATORXS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATORXS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 58 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| ATORXS fundamental statistics | |
|---|---|
| Market cap | SEK 384.75m |
| Earnings (TTM) | -SEK 212.87m |
| Revenue (TTM) | SEK 40.45m |
9.5x
P/S Ratio-1.8x
P/E RatioIs ATORXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATORXS income statement (TTM) | |
|---|---|
| Revenue | SEK 40.45m |
| Cost of Revenue | SEK 169.05m |
| Gross Profit | -SEK 128.59m |
| Other Expenses | SEK 84.28m |
| Earnings | -SEK 212.87m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Jul 13, 2023
| Earnings per share (EPS) | -0.34 |
| Gross Margin | -317.87% |
| Net Profit Margin | -526.20% |
| Debt/Equity Ratio | 0% |
How did ATORXS perform over the long term?
See historical performance and comparison